Lefitolimod vs standard of care (SOC) for patients with metastatic colorectal cancer (mCRC) responding to first-line standard treatment: Results from the randomized phase III IMPALA trial

David Cunningham(Royal Marsden NHS Foundation Trust), Dirk Arnold(Asklepios Klinik Altona), Emanuelly Varea Maria Wiegert(Hospital do Câncer III), C. Tournigand, Michaël Baumann(Kantonsspital St. Gallen), Michel Ducreux(Université Paris-Saclay), M. Starke(Mologen (Germany)), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Alberto F. Sobrero(Ospedale Policlinico San Martino), Manuel Schmidt(Mologen (Germany)), Valéria Molnár(Mologen (Germany)), Werner Scheithauer(Comprehensive Cancer Center Vienna), Ramón Salazar(Institut Català d'Oncologia)
Annals of Oncology
October 1, 2019
10.1093/annonc/mdz394.022
Cited by 6

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k